Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury

Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-S...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2020, Vol.2020 (2020), p.1-5
Main Authors: Shi, Bin, Zhang, Qian, Hou, Guangjian, Cao, Shengnan, Liang, Liangke, Chen, Yuanzhen, Ma, Hong
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Aged
Aged, 80 and over
Analysis
Biological markers
Biomarkers
Biomarkers - blood
Blood pressure
Body mass index
Care and treatment
Case-Control Studies
CCL21 protein
Chemokine CCL21 - blood
Chemokines
Cholesterol
Cognition disorders
Cognitive ability
Cognitive Dysfunction - blood
Cognitive Dysfunction - complications
Correlation analysis
Cytokines
Dementia
Demographics
Demography
Diagnosis
Enzyme-Linked Immunosorbent Assay
Fasting
Female
Gender
Glucose
Humans
Impairment
Ligands
Lipoproteins
Low density lipoprotein
Low density lipoproteins
Male
Mental Status and Dementia Tests
Middle Aged
Multivariate Analysis
Pain
Patients
Prevention
Risk analysis
Risk Factors
Spinal cord injuries
Spinal Cord Injuries - blood
Spinal Cord Injuries - complications
Statistical analysis
Triglycerides
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3
cites cdi_FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3
container_end_page 5
container_issue 2020
container_start_page 1
container_title BioMed research international
container_volume 2020
creator Shi, Bin
Zhang, Qian
Hou, Guangjian
Cao, Shengnan
Liang, Liangke
Chen, Yuanzhen
Ma, Hong
description Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population. Results. A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups (p>0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level (p
doi_str_mv 10.1155/2020/6692802
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7746442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A697105068</galeid><sourcerecordid>A697105068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3</originalsourceid><addsrcrecordid>eNqN0c9rFDEUB_Agii21N88S8CLo2pcfk5m5CHXwx8JChdVzeJPNbLPOJGsy09L_vll33aqn5pLA-_DNezxCXjJ4z1hRXHDgcKFUzSvgT8gpF0zOFJPs6fEtxAk5T2kD-VRMQa2ekxMhRKlKAadkubRxGmjTLDijmCjSb2G0fnTY048uDBh_2ki7EGkT1t6N7sbS-bBFF4esqPN0uXU-4ybEFZ37zRTvXpBnHfbJnh_uM_Lj86fvzdfZ4urLvLlczIys63EmAVuwyG2lEDredpyZksu6ENLKFq3gteGQi6ztBLeIVQdQtLJgTK2MNOKMfNjnbqd2sCuTG4rY6210ue07HdDpfyveXet1uNFlKZWUPAe8OQTE8GuyadSDS8b2PXobpqS5LEUNwArI9PV_dBOmmAf_rWRVVKKqHtQae6ud70L-1-xC9aWqSwYFqJ16t1cmhpSi7Y4tM9C7terdWvVhrZm_-nvMI_6zxAze7sG18yu8dY-Ms9nYDh80E4oxLu4B9GSxPw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474858388</pqid></control><display><type>article</type><title>Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>Shi, Bin ; Zhang, Qian ; Hou, Guangjian ; Cao, Shengnan ; Liang, Liangke ; Chen, Yuanzhen ; Ma, Hong</creator><contributor>Xu, Yuzhen ; Yuzhen Xu</contributor><creatorcontrib>Shi, Bin ; Zhang, Qian ; Hou, Guangjian ; Cao, Shengnan ; Liang, Liangke ; Chen, Yuanzhen ; Ma, Hong ; Xu, Yuzhen ; Yuzhen Xu</creatorcontrib><description>Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population. Results. A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups (p&gt;0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level (p&lt;0.001) and a lower MoCA score (p&lt;0.001). Serum CCL21 level in SCI was negatively correlated with MoCA score (p=0.023). Multivariable analyses showed that serum CCL21 level is an independent prognostic factor of cognitive impairment in SCI. Conclusions. MoCA score has a linear relationship with serum CCL21 quartile, and SCI cognitive function has a negative correlation with serum CCL21. Serum CCL21 is an independent risk factor for cognitive impairment after SCI.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2020/6692802</identifier><identifier>PMID: 33376730</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adolescent ; Adult ; Age ; Aged ; Aged, 80 and over ; Analysis ; Biological markers ; Biomarkers ; Biomarkers - blood ; Blood pressure ; Body mass index ; Care and treatment ; Case-Control Studies ; CCL21 protein ; Chemokine CCL21 - blood ; Chemokines ; Cholesterol ; Cognition disorders ; Cognitive ability ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - complications ; Correlation analysis ; Cytokines ; Dementia ; Demographics ; Demography ; Diagnosis ; Enzyme-Linked Immunosorbent Assay ; Fasting ; Female ; Gender ; Glucose ; Humans ; Impairment ; Ligands ; Lipoproteins ; Low density lipoprotein ; Low density lipoproteins ; Male ; Mental Status and Dementia Tests ; Middle Aged ; Multivariate Analysis ; Pain ; Patients ; Prevention ; Risk analysis ; Risk Factors ; Spinal cord injuries ; Spinal Cord Injuries - blood ; Spinal Cord Injuries - complications ; Statistical analysis ; Triglycerides ; Young Adult</subject><ispartof>BioMed research international, 2020, Vol.2020 (2020), p.1-5</ispartof><rights>Copyright © 2020 Yuanzhen Chen et al.</rights><rights>COPYRIGHT 2020 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2020 Yuanzhen Chen et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Yuanzhen Chen et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3</citedby><cites>FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3</cites><orcidid>0000-0001-9305-5438 ; 0000-0002-3705-1130</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2474858388/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2474858388?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33376730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xu, Yuzhen</contributor><contributor>Yuzhen Xu</contributor><creatorcontrib>Shi, Bin</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Hou, Guangjian</creatorcontrib><creatorcontrib>Cao, Shengnan</creatorcontrib><creatorcontrib>Liang, Liangke</creatorcontrib><creatorcontrib>Chen, Yuanzhen</creatorcontrib><creatorcontrib>Ma, Hong</creatorcontrib><title>Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population. Results. A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups (p&gt;0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level (p&lt;0.001) and a lower MoCA score (p&lt;0.001). Serum CCL21 level in SCI was negatively correlated with MoCA score (p=0.023). Multivariable analyses showed that serum CCL21 level is an independent prognostic factor of cognitive impairment in SCI. Conclusions. MoCA score has a linear relationship with serum CCL21 quartile, and SCI cognitive function has a negative correlation with serum CCL21. Serum CCL21 is an independent risk factor for cognitive impairment after SCI.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>CCL21 protein</subject><subject>Chemokine CCL21 - blood</subject><subject>Chemokines</subject><subject>Cholesterol</subject><subject>Cognition disorders</subject><subject>Cognitive ability</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - complications</subject><subject>Correlation analysis</subject><subject>Cytokines</subject><subject>Dementia</subject><subject>Demographics</subject><subject>Demography</subject><subject>Diagnosis</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Fasting</subject><subject>Female</subject><subject>Gender</subject><subject>Glucose</subject><subject>Humans</subject><subject>Impairment</subject><subject>Ligands</subject><subject>Lipoproteins</subject><subject>Low density lipoprotein</subject><subject>Low density lipoproteins</subject><subject>Male</subject><subject>Mental Status and Dementia Tests</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pain</subject><subject>Patients</subject><subject>Prevention</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Spinal cord injuries</subject><subject>Spinal Cord Injuries - blood</subject><subject>Spinal Cord Injuries - complications</subject><subject>Statistical analysis</subject><subject>Triglycerides</subject><subject>Young Adult</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqN0c9rFDEUB_Agii21N88S8CLo2pcfk5m5CHXwx8JChdVzeJPNbLPOJGsy09L_vll33aqn5pLA-_DNezxCXjJ4z1hRXHDgcKFUzSvgT8gpF0zOFJPs6fEtxAk5T2kD-VRMQa2ekxMhRKlKAadkubRxGmjTLDijmCjSb2G0fnTY048uDBh_2ki7EGkT1t6N7sbS-bBFF4esqPN0uXU-4ybEFZ37zRTvXpBnHfbJnh_uM_Lj86fvzdfZ4urLvLlczIys63EmAVuwyG2lEDredpyZksu6ENLKFq3gteGQi6ztBLeIVQdQtLJgTK2MNOKMfNjnbqd2sCuTG4rY6210ue07HdDpfyveXet1uNFlKZWUPAe8OQTE8GuyadSDS8b2PXobpqS5LEUNwArI9PV_dBOmmAf_rWRVVKKqHtQae6ud70L-1-xC9aWqSwYFqJ16t1cmhpSi7Y4tM9C7terdWvVhrZm_-nvMI_6zxAze7sG18yu8dY-Ms9nYDh80E4oxLu4B9GSxPw</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Shi, Bin</creator><creator>Zhang, Qian</creator><creator>Hou, Guangjian</creator><creator>Cao, Shengnan</creator><creator>Liang, Liangke</creator><creator>Chen, Yuanzhen</creator><creator>Ma, Hong</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9305-5438</orcidid><orcidid>https://orcid.org/0000-0002-3705-1130</orcidid></search><sort><creationdate>2020</creationdate><title>Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury</title><author>Shi, Bin ; Zhang, Qian ; Hou, Guangjian ; Cao, Shengnan ; Liang, Liangke ; Chen, Yuanzhen ; Ma, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>CCL21 protein</topic><topic>Chemokine CCL21 - blood</topic><topic>Chemokines</topic><topic>Cholesterol</topic><topic>Cognition disorders</topic><topic>Cognitive ability</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - complications</topic><topic>Correlation analysis</topic><topic>Cytokines</topic><topic>Dementia</topic><topic>Demographics</topic><topic>Demography</topic><topic>Diagnosis</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Fasting</topic><topic>Female</topic><topic>Gender</topic><topic>Glucose</topic><topic>Humans</topic><topic>Impairment</topic><topic>Ligands</topic><topic>Lipoproteins</topic><topic>Low density lipoprotein</topic><topic>Low density lipoproteins</topic><topic>Male</topic><topic>Mental Status and Dementia Tests</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pain</topic><topic>Patients</topic><topic>Prevention</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Spinal cord injuries</topic><topic>Spinal Cord Injuries - blood</topic><topic>Spinal Cord Injuries - complications</topic><topic>Statistical analysis</topic><topic>Triglycerides</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shi, Bin</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Hou, Guangjian</creatorcontrib><creatorcontrib>Cao, Shengnan</creatorcontrib><creatorcontrib>Liang, Liangke</creatorcontrib><creatorcontrib>Chen, Yuanzhen</creatorcontrib><creatorcontrib>Ma, Hong</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shi, Bin</au><au>Zhang, Qian</au><au>Hou, Guangjian</au><au>Cao, Shengnan</au><au>Liang, Liangke</au><au>Chen, Yuanzhen</au><au>Ma, Hong</au><au>Xu, Yuzhen</au><au>Yuzhen Xu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population. Results. A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups (p&gt;0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level (p&lt;0.001) and a lower MoCA score (p&lt;0.001). Serum CCL21 level in SCI was negatively correlated with MoCA score (p=0.023). Multivariable analyses showed that serum CCL21 level is an independent prognostic factor of cognitive impairment in SCI. Conclusions. MoCA score has a linear relationship with serum CCL21 quartile, and SCI cognitive function has a negative correlation with serum CCL21. Serum CCL21 is an independent risk factor for cognitive impairment after SCI.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>33376730</pmid><doi>10.1155/2020/6692802</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-9305-5438</orcidid><orcidid>https://orcid.org/0000-0002-3705-1130</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2020, Vol.2020 (2020), p.1-5
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7746442
source Publicly Available Content Database; Wiley Open Access
subjects Adolescent
Adult
Age
Aged
Aged, 80 and over
Analysis
Biological markers
Biomarkers
Biomarkers - blood
Blood pressure
Body mass index
Care and treatment
Case-Control Studies
CCL21 protein
Chemokine CCL21 - blood
Chemokines
Cholesterol
Cognition disorders
Cognitive ability
Cognitive Dysfunction - blood
Cognitive Dysfunction - complications
Correlation analysis
Cytokines
Dementia
Demographics
Demography
Diagnosis
Enzyme-Linked Immunosorbent Assay
Fasting
Female
Gender
Glucose
Humans
Impairment
Ligands
Lipoproteins
Low density lipoprotein
Low density lipoproteins
Male
Mental Status and Dementia Tests
Middle Aged
Multivariate Analysis
Pain
Patients
Prevention
Risk analysis
Risk Factors
Spinal cord injuries
Spinal Cord Injuries - blood
Spinal Cord Injuries - complications
Statistical analysis
Triglycerides
Young Adult
title Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T18%3A19%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20CCL21%20as%20a%20Potential%20Biomarker%20for%20Cognitive%20Impairment%20in%20Spinal%20Cord%20Injury&rft.jtitle=BioMed%20research%20international&rft.au=Shi,%20Bin&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2020/6692802&rft_dat=%3Cgale_pubme%3EA697105068%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-40ab0ea2e86a0f2bf21c7249534e4bae329c2086a1bf32eaa8f005b45116dc4c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2474858388&rft_id=info:pmid/33376730&rft_galeid=A697105068&rfr_iscdi=true